Using Vacuum Assisted Biopsy Before Surgery to Check Response to Chemotherapy in Breast Cancer Patients

What this Trial Is About

Researchers are studying the use of vacuum-assisted biopsy VAB to better detect remaining breast cancer tissue after neoadjuvant chemotherapy NAC, which is a common initial treatment for breast cancer. NAC can lead to complete disappearance of the tumor in aggressive cancer types, but current imaging methods cannot reliably predict if any cancer remains. This study aims to compare the accuracy of tissue samples taken by VAB before surgery to the standard surgical tissue samples to see if VAB can serve as a less invasive way to check for residual cancer. Participants will undergo ultrasound- or mammography-guided VAB to sample tissue from the former tumor site after NAC and before standard breast surgery. The trial focuses on patients with certain breast cancer types who show a complete or near-complete response on imaging after chemotherapy. After the biopsy, participants will have breast conserving surgery or mastectomy, and both biopsy and surgical samples will be examined to evaluate the presence of residual cancer. During the study, patients will be monitored closely with imaging before VAB and surgery, and the tissue samples will be analyzed for residual disease. Researchers will measure how accurately VAB detects residual cancer compared to surgery by assessing sensitivity, specificity, and predictive values. Safety will be monitored from the biopsy until two weeks after surgery. The total time from registration to outcome measurement is up to six weeks.

Intelligent Vacuum Assisted Biopsy Immediately Before Surgery As an Intra- or Pre-Operative Surrogate for Patient Response to Neoadjuvant Chemotherapy for Breast Cancer